Clinical features and serum lipidomic profile of patients with nonalcoholic fatty liver disease and healthy individuals in the overweight population

Xiaoyan CHEN; Yifu YUAN; Shengnan DU; Qin CAO; Yuanye JIANG

doi:10.12449/JCH240211

Volume 40 Issue 2

Feb. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(2): 284-291

PDF( 1229 KB)

Clinical features and serum lipidomic profile of patients with nonalcoholic fatty liver disease and healthy individuals in the overweight population

DOI: 10.12449/JCH240211

Department of Gastroenterology，Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 200062，China

Research funding:

Shanghai Natural Science Foundation (22ZR1455900);

Shanghai Health and Family Planning Commission Clinical Research Project (201940449);

Shanghai Putuo District Health System Science and Technology Innovation Project (ptkwws202201);

Shanghai University of Traditional Chinese Medicine Reserve Outstanding Traditional Chinese Medicine Talents Project (20D-RC-02);

Shanghai Famous Traditional Chinese Medicine Putuo Inheritance Studio (ptzygzs2201);

Shanghai Famous Traditional Chinese Medicine Putuo Inheritance Studio (SHGZS-202224);

Shanghai Putuo District Xinglin Excellent Youth Talent Training Program (ptxlyq2201)

More Information

Corresponding author: JIANG Yuanye， yuanye1014@126.com （ORCID： 0000-0002-4979-4206）
Received Date: 2023-05-14
Accepted Date: 2023-06-25
Published Date: 2024-02-19

Abstract

Abstract

objective To investigate the differences in clinical indices and lipid metabolism between the patients with nonalcoholic fatty liver disease （NAFLD） and healthy individuals in the overweight population. Methods In this study， body mass index （BMI）>23 kg/m² was defined as overweight. A total of 62 overweight patients with NAFLD who were admitted to Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from August 2020 to April 2021 were enrolled as overweight NAFLD group， and 50 overweight individuals who underwent physical examination during the same period of time were enrolled as control group. Clinical information and blood biochemical parameters were recorded for all subjects. Ultra-performance liquid chromatography-tandem mass spectrometry was used to analyze serum lipidomic profile， and principal component analysis and orthogonal partial least squares-discriminant analysis were used to perform the multivariate statistical analysis of lipidomic data. The chi-square test was used for comparison of categorical data between two groups， and the independent-samples t test or the Wilcoxon rank-sum test was used for comparison of continuous data between two groups. Results The overweight NAFLD group had a significantly higher BMI than the overweight control group （Z=-2.365， P=0.018）. As for serological markers， compared with the overweight control group， the overweight NAFLD group had significantly higher levels of red blood cells， hemoglobin， hematocrit， uric acid， total protein， globulin， alkaline phosphatase， gamma-glutamyl transpeptidase， alanine aminotransferase， aspartate aminotransferase， cholinesterase， low-density lipoprotein， total cholesterol， triglyceride， apolipoprotein B， and blood glucose （all P<0.05）. The lipidomic analysis showed that there was a significant difference in lipid metabolism between the two groups， and a total of 493 differentially expressed lipids were identified （VIP value>1， P<0.05）， among which 143 lipids were significantly upregulated and 350 lipids were significantly downregulated in the overweight NAFLD group. The mean total fatty acid content in the overweight NAFLD group was 3.6 times that in the overweight control group. Compared with the overweight control group， the overweight NAFLD group had a significant reduction in the content of triglyceride with>3 unsaturated bonds （P<0.001） and a significant increase in the content of triglyceride with ≤3 unsaturated bonds （P<0.001）. Conclusion Compared with healthy overweight individuals， overweight NAFLD patients tend to have significant abnormalities in some biochemical parameters and lipid metabolites， with significant increases in the content of fatty acid in blood and the types of saturated fat chains in triglycerides.
- Non-Alcoholic Fatty Liver Disease,
- Overweight,
- Signs and Symptoms,
- Lipidomics

FullText(HTML)

References(23)

References

[1]	LI L, LIU DW, YAN HY, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies[J]. Obes Rev, 2016, 17( 6): 510- 519. DOI: 10.1111/obr.12407.
[2]	FAN JG, KIM SU, WONG VW. New trends on obesity and NAFLD in Asia[J]. J Hepatol, 2017, 67( 4): 862- 873. DOI: 10.1016/j.jhep.2017.06.003.
[3]	IACOBINI C, PUGLIESE G, BLASETTI FANTAUZZI C, et al. Metabolically healthy versus metabolically unhealthy obesity[J]. Metabolism, 2019, 92: 51- 60. DOI: 10.1016/j.metabol.2018.11.009.
[4]	OLIVEIRA DT, CHAVES-FILHO AB, YOSHINAGA MY, et al. Liver lipidome signature and metabolic pathways in nonalcoholic fatty liver disease induced by a high-sugar diet[J]. J Nutr Biochem, 2021, 87: 108519. DOI: 10.1016/j.jnutbio.2020.108519.
[5]	MASOODI M, GASTALDELLI A, HYÖTYLÄINEN T, et al. Metabolomics and lipidomics in NAFLD: Biomarkers and non-invasive diagnostic tests[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 12): 835- 856. DOI: 10.1038/s41575-021-00502-9.
[6]	TIAN JY, DU SN, GAO JJ, et al. Study on serum lipidomics of non-alcoholic fatty liver disease patients based on UPLC-Q-Orbitrap/MS technology[J]. China Med Herald, 2022, 19( 19): 5- 11. 田继云, 杜晟楠, 高静静, 等. 基于UPLC-Q-Orbitrap/MS技术对非酒精性脂肪性肝病患者的血清脂质组学研究[J]. 中国医药导报, 2022, 19( 19): 5- 11.
[7]	ESLAM M, SARIN SK, WONG VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020, 14( 6): 889- 919. DOI: 10.1007/s12072-020-10094-2.
[8]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[9]	DING QP, ZHOU YB, ZHANG S, et al. Association between hemoglobin levels and non-alcoholic fatty liver disease in patients with young-onset type 2 diabetes mellitus[J]. Endocr J, 2020, 67( 11): 1139- 1146. DOI: 10.1507/endocrj.EJ20-0071.
[10]	LI GL, HU H, SHI W, et al. Elevated hematocrit in nonalcoholic fatty liver disease: A potential cause for the increased risk of cardiovascular disease?[J]. Clin Hemorheol Microcirc, 2012, 51( 1): 59- 68. DOI: 10.3233/CH-2011-1509.
[11]	JIANG YZ, ZENG J, CHEN B. Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver[J]. J Gastroenterol Hepatol, 2014, 29( 7): 1508- 1514. DOI: 10.1111/jgh.12580.
[12]	KIM K, KANG K, SHEOL H, et al. The association between serum uric acid levels and 10-year cardiovascular disease risk in non-alcoholic fatty liver disease patients[J]. Int J Environ Res Public Health, 2022, 19( 3): 1042. DOI: 10.3390/ijerph19031042.
[13]	ZHOU MM, YANG N, XING X, et al. Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease[J]. BMC Gastroenterol, 2021, 21( 1): 43. DOI: 10.1186/s12876-021-01615-w.
[14]	SOUZA-MELLO V, GREGÓRIO BM, CARDOSO-DE-LEMOS FS, et al. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet[J]. Clin Sci(Lond), 2010, 119( 6): 239- 250. DOI: 10.1042/CS20100061.
[15]	GAGGINI M, MORELLI M, BUZZIGOLI E, et al. Non-alcoholic fatty liver disease(NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease[J]. Nutrients, 2013, 5( 5): 1544- 1560. DOI: 10.3390/nu5051544.
[16]	WANG TY, WANG RF, BU ZY, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease[J]. Nat Rev Nephrol, 2022, 18( 4): 259- 268. DOI: 10.1038/s41581-021-00519-y.
[17]	TONG C, LI YN, GU D, et al. The association between obesity measurement indices and nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37( 10): 2465- 2468. DOI: 10.3969/j.issn.1001-5256.2021.10.044. 童聪, 李亚年, 顾达, 等. 人体肥胖测量指标与非酒精性脂肪性肝病的相关性[J]. 临床肝胆病杂志, 2021, 37( 10): 2465- 2468. DOI: 10.3969/j.issn.1001-5256.2021.10.044.
[18]	WANG WT, REN JP, ZHOU WZ, et al. Lean non-alcoholic fatty liver disease(Lean-NAFLD) and the development of metabolic syndrome: A retrospective study[J]. Sci Rep, 2022, 12( 1): 10977. DOI: 10.1038/s41598-022-14701-0.
[19]	MOCCIARO G, ALLISON M, JENKINS B, et al. Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins(HDL)[J]. Mol Metab, 2023, 73: 101728. DOI: 10.1016/j.molmet.2023.101728.
[20]	BARR J, CABALLERÍA J, MARTÍNEZ-ARRANZ I, et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression[J]. J Proteome Res, 2012, 11( 4): 2521- 2532. DOI: 10.1021/pr201223p.
[21]	OREŠIČ M, HYÖTYLÄINEN T, KOTRONEN A, et al. Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids[J]. Diabetologia, 2013, 56( 10): 2266- 2274. DOI: 10.1007/s00125-013-2981-2.
[22]	DONNELLY KL, SMITH CI, SCHWARZENBERG SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease[J]. J Clin Invest, 2005, 115( 5): 1343- 1351. DOI: 10.1172/JCI23621.
[23]	SHIMOMURA I, BASHMAKOV Y, HORTON JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus[J]. J Biol Chem, 1999, 274( 42): 30028- 30032. DOI: 10.1074/jbc.274.42.30028.

Relative Articles

[1]	Jiahao CHEN, Zhenhua ZHOU. Effect of Qizhu prescription on a mouse model of non-alcoholic fatty liver disease incluced by high-fat， high-fructose， and high-cholesterol diet and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(11): 2205-2212. doi: 10.12449/JCH241113
[2]	Tingting DU, Hui YAO, Xiaohong CHEN, Jie LUO, Luhong YANG, Lifang FENG, Xiaoqian CHEN, Man HU, Juan LUO. Clinical features of hypopituitarism with nonalcoholic fatty liver disease after sellar tumor surgery in children[J]. Journal of Clinical Hepatology, 2023, 39(6): 1332-1339. doi: 10.3969/j.issn.1001-5256.2023.06.013
[3]	Shaojie DUAN, Zunjing LIU, Jialiang CHEN, Shukun YAO. Value of lipid accumulation product and visceral fat index in predicting nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(1): 129-134. doi: 10.3969/j.issn.1001-5256.2022.01.020
[4]	Meiying LI, Wanli JI, Wangzhenzu LIU, Tao WANG, Shengnan DU, Jingjing GAO, Yuanye JIANG, Cheng HU. A serum metabolomics study on the intervention of nonalcoholic fatty liver disease by equicaloric low-carbohydrate high-protein diet combined with aerobic exercise[J]. Journal of Clinical Hepatology, 2021, 37(11): 2605-2610. doi: 10.3969/j.issn.1001-5256.2021.11.023
[5]	Qin LIU, Qiang ZHANG, Fangxiong WU, Rong YAN, Rong LI, Jia WANG, Chunyan NIU. Effect of amitriptyline on lipid deposition and biochemical metabolism in a cell model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(1): 99-104. doi: 10.3969/j.issn.1001-5256.2021.01.020
[6]	Yuting LUAN, Zhongming HUANG, Wenjuan SHEN, Minghao HA, Zhibing XU. Research advances in metabolomics in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(4): 943-946. doi: 10.3969/j.issn.1001-5256.2021.04.047
[7]	ZHANG SuYan, XIA EnRui, ZHOU QingLi, ZHANG ShunZhen. Effect of Quzhi Ruangan decoction on the mRNA and protein expression of organic anion transporting polypeptide 2B1 in the small intestine of rats with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2484-2488. doi: 10.3969/j.issn.1001-5256.2020.11.017
[8]	GUO Tao, HU Bo, YI WeiMin, ZHONG ZhenDong, LIU SuLai, SUN ZengPeng, PENG Chuang. Research advances in the serological diagnosis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2579-2583. doi: 10.3969/j.issn.1001-5256.2020.11.041
[9]	Gao JingJing, Wang Tao, Jiang YuanYe, Cao Qin. Metabonomics and traditional Chinese medicine syndrome of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(8): 1880-1882. doi: 10.3969/j.issn.1001-5256.2020.08.044
[10]	Liu Tao, Xu QiuLing. Spleen-strengthening and dampness-removing therapy exerts a therapeutic effect on nonalcoholic fatty liver disease by regulating hepatic MTP promoter methylation[J]. Journal of Clinical Hepatology, 2019, 35(3): 661-664. doi: 10.3969/j.issn.1001-5256.2019.03.047
[11]	Zhu WeiMei, Wang XiuFang, Yang HaiQing, Yang HongLing, Li XueZhang, Pan Yue. Influence of low-level lead exposure on liver function and blood lipids in rats with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(4): 840-845. doi: 10.3969/j.issn.1001-5256.2019.04.026
[12]	Li ZhangXin, Zhou Tao, Niu KeMin, Chen Jing, Wei BeiHai, Wang Jia, Meng SiHong, Li QinNa, Zheng Jiao, Shen QingYan, Chen RuiLin. Effect of liver-regulating and spleen-strengthening method on lipid metabolism and expression of microtubule-associated protein light chain 3B in a rat model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(4): 829-835. doi: 10.3969/j.issn.1001-5256.2018.04.027
[13]	Hong Jia, Shi YiWen, Wu XiaoNing, You Hong. Application value of imaging diagnosis in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(12): 2698-2701. doi: 10.3969/j.issn.1001-5256.2018.12.041
[14]	Li Jie. Epidemiology characteristics of nonalcoholic fatty liver disease in Asia[J]. Journal of Clinical Hepatology, 2018, 34(12): 2515-2519. doi: 10.3969/j.issn.1001-5256.2018.12.006
[15]	Wang Yi. Role of imaging techniques in clinical research and practice on nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2307-2310. doi: 10.3969/j.issn.1001-5256.2017.12.010
[16]	Jiang LiNa, Zhao JingMin. Role of histological evaluation of the liver in clinical practice and research on nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2303-2306. doi: 10.3969/j.issn.1001-5256.2017.12.009
[17]	Wang Yan, Hou JinLin. Hepatic fibrosis in nonalcoholic fatty liver disease and its quantitative assessment[J]. Journal of Clinical Hepatology, 2017, 33(12): 2296-2302. doi: 10.3969/j.issn.1001-5256.2017.12.008
[18]	Ding YuPing, Li Hai, Zhang Wen, Xia ShiHai, Bi Xun. Epidemiological characteristics of nonalcoholic fatty liver disease with elevated alanine aminotransferase and related risk factors[J]. Journal of Clinical Hepatology, 2017, 33(12): 2355-2360. doi: 10.3969/j.issn.1001-5256.2017.12.020
[19]	Liu YingLi, Zhang QiuZan. An excerpt of the Asia-Pacific Working Party on nonalcoholic fatty liver disease guidelines 2017[J]. Journal of Clinical Hepatology, 2017, 33(12): 2278-2282. doi: 10.3969/j.issn.1001-5256.2017.12.004
[20]	Li YanLi, Zhao Yan, Zhao DanTong, Zhang HaiPing, Sun LiMei, Ma YinXue, Hu WenJing, Yan HuiPing. Age-related clinical features of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2013, 29(2): 146-149.

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 朱媛媛，高璐，王珊，李时杰，高敏，王嘉希. 脂质组学技术在痤疮分级和性别差异中的研究. 现代生物医学进展. 2024(21): 4057-4063 .
Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(5) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (510) PDF downloads(71)

Clinical features and serum lipidomic profile of patients with nonalcoholic fatty liver disease and healthy individuals in the overweight population

DOI: 10.12449/JCH240211

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(4)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical features and serum lipidomic profile of patients with nonalcoholic fatty liver disease and healthy individuals in the overweight population

DOI: 10.12449/JCH240211

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(4)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content